Limb-girdle muscular dystrophy type 2I
Alternate names[edit]
Autosomal recessive limb-girdle muscular dystrophy type 2I; LGMD2I; Limb-girdle muscular dystrophy due to FKRP deficiency; Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5 ; FKRP-related limb-girdle muscular dystrophy R9; FKRP-related LGMD R9; LGMD due to FKRP deficiency; LGMD type 2I
Definition[edit]
Limb-girdle muscular dystrophy type 2I (LGMD2I) is a form of limb-girdle muscular dystrophy, which refers to a group of conditions that cause weakness and wasting of the muscles in the arms and legs. The proximal muscles (those closest to the body such as the upper arms and thighs) are generally most affected by the condition.
Epidemiology[edit]
It is difficult to determine the prevalence of limb-girdle muscular dystrophy because its features vary and overlap with those of other muscle disorders. Prevalence estimates range from 1 in 14,500 to 1 in 123,000 individuals.
Cause[edit]
LGMD2I is caused by changes (mutations) in the FKRP gene.
Inheritance[edit]

It is inherited in an autosomal recessive manner.
Onset[edit]
In LGMD2I, specifically, signs and symptoms often develop in late childhood (average age 11.5 years) and may include difficulty running and walking. The symptoms gradually worsen overtime and affected people generally rely on a wheelchair for mobility approximately 23-26 years after onset.
Signs and symptoms[edit]
For most diseases, symptoms will vary from person to person. People with the same disease may not have all the symptoms listed.
80%-99% of people have these symptoms
- Elevated serum creatine kinase(Elevated blood creatine phosphokinase)
- Muscular dystrophy
- Proximal muscle weakness(Weakness in muscles of upper arms and upper legs)
- Reduced muscle fiber alpha dystroglycan
30%-79% of people have these symptoms
- Abnormality of the Achilles tendon
- Calf muscle hypertrophy(Increased size of calf muscles)
- Generalized hypotonia(Decreased muscle tone)
- Pelvic girdle muscle weakness
- Shoulder girdle muscle weakness(Weak shoulder muscles)
- Waddling gait('Waddling' gait)
5%-29% of people have these symptoms
- Difficulty climbing stairs(Difficulty walking up stairs)
- Difficulty running
- Dilated cardiomyopathy(Stretched and thinned heart muscle)
- Frequent falls
- Motor delay
- Reduced muscle fiber merosin
- Scoliosis
1%-4% of people have these symptoms
- Exercise-induced myoglobinuria
Diagnosis[edit]
Molecular Genetics Tests
- Targeted variant analysis
- Deletion/duplication analysis
- Sequence analysis of select exons
- Sequence analysis of the entire coding region
Treatment[edit]
There is, unfortunately, no cure for LGMD2I and treatment is based on the signs and symptoms present in each person.
| Muscular dystrophy | ||||||||
|---|---|---|---|---|---|---|---|---|
* Category
|
| Diseases of muscle, neuromuscular junction, and neuromuscular disease | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Inherited disorders of trafficking / vesicular transport proteins | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
See also vesicular transport proteins
|
| Cell membrane protein disorders (other than Cell surface receptor, enzymes, and cytoskeleton) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
See also other cell membrane proteins
|
NIH genetic and rare disease info[edit]
Limb-girdle muscular dystrophy type 2I is a rare disease.
| Rare and genetic diseases | ||||||
|---|---|---|---|---|---|---|
|
Rare diseases - Limb-girdle muscular dystrophy type 2I
|
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
